NASDAQ:OVID Ovid Therapeutics (OVID) Stock Price, News & Analysis $2.33 -0.07 (-2.92%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.38 +0.04 (+1.93%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ovid Therapeutics Stock (NASDAQ:OVID) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ovid Therapeutics alerts:Sign Up Key Stats Today's Range$2.31▼$2.4050-Day Range$2.21▼$2.7652-Week Range$0.47▼$3.11Volume984,942 shsAverage Volume1.73 million shsMarket Capitalization$434.87 millionP/E RatioN/ADividend YieldN/APrice Target$5.13Consensus RatingModerate Buy Company Overview Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need. The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome. OV101 has demonstrated proof-of-concept activity in early clinical studies, and ongoing trials aim to further characterize its safety and efficacy profiles. In parallel, Ovid is advancing OV935, a small-molecule inhibitor targeting specific kinase pathways implicated in CDKL5 deficiency disorder, a severe form of early-onset epilepsy. To support its global development strategy, Ovid has established strategic collaborations with industry partners. A notable agreement grants regional rights for OV935 to a leading pharmaceutical company for select Asian markets. The company maintains additional research partnerships to broaden its preclinical pipeline and leverage external expertise in rare disease biology and regulatory science. Ovid Therapeutics completed its initial public offering on the Nasdaq market in 2018 and continues to engage with regulatory authorities to advance its clinical programs toward potential approval. The organization is led by a management team with deep experience in neuroscience drug discovery and development, supported by a board of directors comprised of seasoned professionals in biopharma innovation and commercialization.AI Generated. May Contain Errors. Read More Ovid Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreOVID MarketRank™: Ovid Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 647th out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingOvid Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOvid Therapeutics has a consensus price target of $5.13, representing about 120.0% upside from its current price of $2.33.Amount of Analyst CoverageOvid Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Ovid Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ovid Therapeutics are expected to decrease in the coming year, from ($0.50) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ovid Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.70% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 12.65, which indicates bearish sentiment.Change versus previous monthShort interest in Ovid Therapeutics has recently increased by 0.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.95 News SentimentOvid Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ovid Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for OVID on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows4 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.00% of the stock of Ovid Therapeutics is held by insiders.Percentage Held by Institutions72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ovid Therapeutics' insider trading history. Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OVID Stock News HeadlinesWall Street Zen Downgrades Ovid Therapeutics (NASDAQ:OVID) to SellJuly 25 at 1:37 AM | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) Short Interest UpdateJuly 17, 2026 | americanbankingnews.comThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the project. Unocal and Texaco did the same. All three buried the results because it threatened their core business. Now one company has spent sixty years developing what Big Oil refused to touch. Google locked in a 15-year contract, Bill Gates wrote a $100 million check, and on August 18th the government hands it a competitive edge no other energy source receives.July 26 at 1:00 AM | Behind the Markets (Ad)Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business OfficerJuly 14, 2026 | insidermonkey.comOvid Therapeutics Boosts Capital Through Warrant ExercisesJuly 9, 2026 | theglobeandmail.comOvid Therapeutics Promotes Charles Carter to Chief Financial Officer in Leadership ShuffleJuly 8, 2026 | marketwatch.comOvid Therapeutics appoints Charles Carter as new CFOJuly 8, 2026 | tipranks.comOvid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of DevelopmentJuly 8, 2026 | globenewswire.comSee More Headlines OVID Stock Analysis - Frequently Asked Questions How have OVID shares performed this year? Ovid Therapeutics' stock was trading at $1.63 at the beginning of 2026. Since then, OVID shares have increased by 42.9% and is now trading at $2.33. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics (NASDAQ:OVID) released its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). Ovid Therapeutics had a negative net margin of 240.11% and a negative trailing twelve-month return on equity of 22.51%. When did Ovid Therapeutics IPO? Ovid Therapeutics (OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Top institutional shareholders of Ovid Therapeutics include Assenagon Asset Management S.A. (0.01%). Insiders that own company stock include Jeremy M Levin and Margaret A Alexander. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ovid Therapeutics investors own include Plug Power (PLUG), Alamos Gold (AGI), FuelCell Energy (FCEL), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Workhorse Group (WKHS). Company Calendar Last Earnings5/12/2026Today7/26/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 OVID's financial health is in the Green zone, according to TradeSmith. OVID has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OVID CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees60Year Founded2014Price Target and Rating Average Price Target for Ovid Therapeutics$5.13 High Price Target$7.00 Low Price Target$3.00 Potential Upside/Downside+120.0%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.41 million Net Margins-240.11% Pretax Margin-339.33% Return on Equity-22.51% Return on Assets-18.67% Debt Debt-to-Equity Ratio0.06 Current Ratio10.17 Quick Ratio10.17 Sales & Book Value Annual Sales$7.25 million Price / Sales59.98 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book2.33Miscellaneous Outstanding Shares186,640,000Free Float173,575,000Market Cap$434.87 million OptionableOptionable Beta0.18 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:OVID) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBlackRock's $2.8B Clue (most investors missed)BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...Awesomely | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredAugust 6 could be a BIG day for one AI companyOne AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...InvestorPlace | SponsoredThe invention Elon called the greatest in historyJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OVID Stock Alerts